MedTrace Logo

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

NCT02402452 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-03-20

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly GS-9857) in participants with severe renal impairment and matched healthy control participants.

Conditions

  • HCV Infection

Interventions

DRUG

Voxilaprevir

100 mg tablet administered orally

Sponsors & Collaborators

Principal Investigators

  • Gilead Study Director, MD, PhD · Gilead Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-05
Primary Completion
2015-09-28
Completion
2015-09-28

Countries

  • United States
  • Germany
  • New Zealand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02402452 on ClinicalTrials.gov